CA2597673C - Methods and compositions for detecting a drug resistant egfr mutant - Google Patents

Methods and compositions for detecting a drug resistant egfr mutant Download PDF

Info

Publication number
CA2597673C
CA2597673C CA2597673A CA2597673A CA2597673C CA 2597673 C CA2597673 C CA 2597673C CA 2597673 A CA2597673 A CA 2597673A CA 2597673 A CA2597673 A CA 2597673A CA 2597673 C CA2597673 C CA 2597673C
Authority
CA
Canada
Prior art keywords
egfr
mutation
mutant
sequence
gefitinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2597673A
Other languages
English (en)
French (fr)
Other versions
CA2597673A1 (en
Inventor
Harold Varmus
Katerina Politi
William Pao
Vincent Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36793833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2597673(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CA2597673A1 publication Critical patent/CA2597673A1/en
Application granted granted Critical
Publication of CA2597673C publication Critical patent/CA2597673C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2597673A 2005-02-11 2006-02-13 Methods and compositions for detecting a drug resistant egfr mutant Expired - Lifetime CA2597673C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65248805P 2005-02-11 2005-02-11
US60/652,488 2005-02-11
PCT/US2006/005050 WO2006086777A2 (en) 2005-02-11 2006-02-13 Methods and compositions for detecting a drug resistant egfr mutant

Publications (2)

Publication Number Publication Date
CA2597673A1 CA2597673A1 (en) 2006-08-17
CA2597673C true CA2597673C (en) 2014-07-08

Family

ID=36793833

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2597673A Expired - Lifetime CA2597673C (en) 2005-02-11 2006-02-13 Methods and compositions for detecting a drug resistant egfr mutant

Country Status (7)

Country Link
US (2) US8067175B2 (https=)
EP (2) EP1851339B1 (https=)
JP (2) JP4898710B2 (https=)
CN (1) CN101193905B (https=)
CA (1) CA2597673C (https=)
ES (1) ES2586410T3 (https=)
WO (1) WO2006086777A2 (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101193905B (zh) * 2005-02-11 2014-06-25 纪念斯隆-凯特林癌症中心 用于检测抗药egfr突变体的方法和组合物
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
US8273534B2 (en) 2008-05-14 2012-09-25 Genomic Health, Inc. Predictors of patient response to treatment with EGF receptor inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
US9156010B2 (en) 2008-09-23 2015-10-13 Bio-Rad Laboratories, Inc. Droplet-based assay system
US11130128B2 (en) 2008-09-23 2021-09-28 Bio-Rad Laboratories, Inc. Detection method for a target nucleic acid
US9492797B2 (en) 2008-09-23 2016-11-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US9764322B2 (en) 2008-09-23 2017-09-19 Bio-Rad Laboratories, Inc. System for generating droplets with pressure monitoring
US9132394B2 (en) 2008-09-23 2015-09-15 Bio-Rad Laboratories, Inc. System for detection of spaced droplets
US8709762B2 (en) 2010-03-02 2014-04-29 Bio-Rad Laboratories, Inc. System for hot-start amplification via a multiple emulsion
US9399215B2 (en) 2012-04-13 2016-07-26 Bio-Rad Laboratories, Inc. Sample holder with a well having a wicking promoter
US10512910B2 (en) 2008-09-23 2019-12-24 Bio-Rad Laboratories, Inc. Droplet-based analysis method
WO2011120006A1 (en) 2010-03-25 2011-09-29 Auantalife, Inc. A Delaware Corporation Detection system for droplet-based assays
US12090480B2 (en) 2008-09-23 2024-09-17 Bio-Rad Laboratories, Inc. Partition-based method of analysis
WO2011120024A1 (en) 2010-03-25 2011-09-29 Quantalife, Inc. Droplet generation for droplet-based assays
CA2738578C (en) 2008-09-23 2021-05-04 Quantalife, Inc. Droplet-based assay system
US8951939B2 (en) 2011-07-12 2015-02-10 Bio-Rad Laboratories, Inc. Digital assays with multiplexed detection of two or more targets in the same optical channel
US12162008B2 (en) 2008-09-23 2024-12-10 Bio-Rad Laboratories, Inc. Partition-based method of analysis
US9598725B2 (en) 2010-03-02 2017-03-21 Bio-Rad Laboratories, Inc. Emulsion chemistry for encapsulated droplets
US8633015B2 (en) 2008-09-23 2014-01-21 Bio-Rad Laboratories, Inc. Flow-based thermocycling system with thermoelectric cooler
US9417190B2 (en) 2008-09-23 2016-08-16 Bio-Rad Laboratories, Inc. Calibrations and controls for droplet-based assays
CN101463390B (zh) * 2008-12-31 2011-09-14 广州益善生物技术有限公司 Egfr基因外显子20突变的检测探针、液相芯片及其检测方法
IL313131A (en) * 2009-02-11 2024-07-01 Caris Mpi Inc Molecular characterization of tumors
CN101608240B (zh) * 2009-04-13 2011-06-29 郑立谋 用于检测人类egfr基因突变的引物、探针及其使用方法
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
EP2473618B1 (en) 2009-09-02 2015-03-04 Bio-Rad Laboratories, Inc. System for mixing fluids by coalescence of multiple emulsions
CN102021232A (zh) * 2009-09-22 2011-04-20 北京雅康博生物科技有限公司 用于定量检测egfr突变的试剂盒
WO2011052754A1 (ja) * 2009-10-30 2011-05-05 アークレイ株式会社 Ｅｇｆｒ遺伝子多型検出用プローブおよびその用途
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
EP2542692B1 (en) 2010-03-04 2016-08-24 Carpén, Olli Method for selecting patients for treatment with an egfr inhibitor
JP6155419B2 (ja) 2010-03-25 2017-07-05 バイオ−ラッド・ラボラトリーズ・インコーポレーテッド 検出用の液滴輸送システム
CN102234683B (zh) * 2010-04-23 2013-07-17 广州益善生物技术有限公司 一种egfr基因突变检测液相芯片
CN105566229A (zh) 2010-08-10 2016-05-11 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐及其用途和制备方法
WO2012023138A2 (en) * 2010-08-18 2012-02-23 Technion Research And Development Foundation Ltd. Volatile organic compounds for detecting cell dysplasia and genetic alterations associated with lung cancer
JP5860667B2 (ja) 2010-10-29 2016-02-16 アークレイ株式会社 Ｅｇｆｒエクソン２１ｌ８５８ｒ遺伝子多型検出用プライマーセット及びその用途
CN103429331B (zh) 2010-11-01 2016-09-28 伯乐生命医学产品有限公司 用于形成乳液的系统
MX382354B (es) 2010-11-01 2025-03-13 Celgene Car Llc Compuestos heterocíclicos y usos de los mismos.
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP5957003B2 (ja) 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 変異体選択的ｅｇｆｒ阻害剤およびその使用
EP2468883A1 (en) * 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US12097495B2 (en) 2011-02-18 2024-09-24 Bio-Rad Laboratories, Inc. Methods and compositions for detecting genetic material
AU2012231098B2 (en) 2011-03-18 2016-09-29 Bio-Rad Laboratories, Inc. Multiplexed digital assays with combinatorial use of signals
US9347059B2 (en) 2011-04-25 2016-05-24 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
EP2737089B1 (en) 2011-07-29 2017-09-06 Bio-rad Laboratories, Inc. Library characterization by digital assay
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
CN103184274A (zh) * 2011-12-27 2013-07-03 上海复星医学科技发展有限公司 一种ldr技术的egfr突变检测试剂盒
KR102081042B1 (ko) 2012-03-15 2020-02-26 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 고체 형태
PL2825042T3 (pl) 2012-03-15 2019-02-28 Celgene Car Llc Sole inhibitora kinazy receptora czynnika wzrostu naskórka
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
AU2014214846A1 (en) 2013-02-08 2015-07-23 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US20140287417A1 (en) 2013-03-08 2014-09-25 Roche Molecular Systems, Inc. EGFR Blood Monitoring
ES2662598T3 (es) 2013-03-08 2018-04-09 F. Hoffmann-La Roche Ag Análisis de sangre para la detección de mutaciones de EGFR
WO2014147631A1 (en) 2013-03-22 2014-09-25 Natco Pharma Limited Formulation comprising gefitinib as oral suspension
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
GB201402996D0 (en) * 2014-02-20 2014-04-09 Vela Operations Pte Ltd Variant analysis in high-throughput sequencing applications
US20170191118A1 (en) * 2014-06-03 2017-07-06 The Regents Of The University Of California Non-Invasive Gene Mutation Detection in Lung Cancer Patients
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
CN106498028B (zh) * 2016-05-26 2020-06-30 格诺思博生物科技南通有限公司 Egfr的t790m突变的诊断方法及试剂盒
EP3464638B1 (en) * 2016-06-03 2023-12-06 Singapore Health Services Pte Ltd Use of biomarkers in determining susceptibility to egfr inhibitors
CN106498029B (zh) * 2016-06-20 2020-05-19 格诺思博生物科技南通有限公司 提高egfr的t790m突变的诊断效率的方法
JP2018088883A (ja) * 2016-12-06 2018-06-14 東洋紡株式会社 上皮成長因子受容体遺伝子変異の検出方法
CN106811522A (zh) * 2016-12-26 2017-06-09 北京奥维森基因科技有限公司 用于检测以egfp为靶点的药物相关基因耐药位点的pcr引物组及其应用和检测试剂盒
US9980967B1 (en) 2017-03-16 2018-05-29 National Chiao Tung University Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
CN106906295B (zh) * 2017-03-31 2020-12-08 天津诺禾致源生物信息科技有限公司 数字pcr检测基因点突变方法及装置
CN108546748A (zh) * 2017-04-05 2018-09-18 杭州丹威生物科技有限公司 一种检测核酸的方法和试剂盒
CN109722478A (zh) * 2017-10-31 2019-05-07 嘉兴雅康博医学检验所有限公司 用于检测egfr基因2312-2313位突变的引物、探针及试剂盒
JP6933768B2 (ja) 2018-03-15 2021-09-08 栄研化学株式会社 一塩基多型検出用オリゴヌクレオチドプローブ、及びシス型−トランス型判別方法
SG11202108311RA (en) 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
CN111748026A (zh) * 2019-03-29 2020-10-09 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
PH12022552076A1 (en) 2020-02-12 2023-11-29 Janssen Biotech Inc TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS
KR20230039608A (ko) * 2020-05-07 2023-03-21 더 리전츠 오브 더 유니버시티 오브 캘리포니아 혈장 및 타액의 액체 생검 플랫폼

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4182124A (en) 1977-01-28 1980-01-08 Kraus Edmund J Gravity augmented air compression turbine power plant
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
CA1142466A (en) 1979-01-09 1983-03-08 National Research Development Corporation Cell lines
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US5030565A (en) 1983-08-17 1991-07-09 Scripps Clinic And Research Foundation Polypeptide-induced monoclonal receptors to protein ligands
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5561058A (en) 1986-08-22 1996-10-01 Hoffmann-La Roche Inc. Methods for coupled high temperatures reverse transcription and polymerase chain reactions
CA1339731C (en) 1988-10-12 1998-03-17 Charles T. Caskey Multiplex genomic dna amplification for deletion detection
US5223168A (en) 1989-12-12 1993-06-29 Gary Holt Surface cleaner and treatment
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5506351A (en) 1992-07-23 1996-04-09 Isis Pharmaceuticals Process for the preparation of 2'-O-alkyl guanosine and related compounds
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
DE69108716T2 (de) 1990-01-26 1995-08-17 Washington Research Foundation, Seattle, Wash. Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
US5852184A (en) 1990-11-28 1998-12-22 Ludwig Institute For Cancer Research Protein tyrosine kinase
US5610276A (en) 1991-05-17 1997-03-11 Chiron Corporation Polypeptides and antibodies derived from GAP associated protein, p62
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5599797A (en) 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5633134A (en) 1992-10-06 1997-05-27 Ig Laboratories, Inc. Method for simultaneously detecting multiple mutations in a DNA sample
US5405941A (en) 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US5571902A (en) 1993-07-29 1996-11-05 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5554746A (en) 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5589330A (en) 1994-07-28 1996-12-31 Genzyme Corporation High-throughput screening method for sequence or genetic alterations in nucleic acids using elution and sequencing of complementary oligonucleotides
US5939269A (en) 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
US6066625A (en) 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
US6503754B1 (en) 2000-09-07 2003-01-07 Isis Pharmaceuticals, Inc. Antisense modulation of BH3 interacting domain death agonist expression
US7521175B2 (en) 2001-06-14 2009-04-21 The Regents Of The University Of California Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
CN101501211A (zh) 2004-03-31 2009-08-05 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
EP1766068A4 (en) 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
CN101193905B (zh) * 2005-02-11 2014-06-25 纪念斯隆-凯特林癌症中心 用于检测抗药egfr突变体的方法和组合物
MX2007009963A (es) 2005-02-24 2007-09-26 Amgen Inc Mutaciones del receptor del factor de crecimiento epidermico.
EP1881079A1 (en) 2006-07-20 2008-01-23 Pangaea Biotech, S.A. Method for the detection of EGFR mutations in blood samples

Also Published As

Publication number Publication date
CN101193905B (zh) 2014-06-25
CN101193905A (zh) 2008-06-04
CA2597673A1 (en) 2006-08-17
EP1851339A4 (en) 2009-05-27
WO2006086777A3 (en) 2007-11-22
US8501413B2 (en) 2013-08-06
WO2006086777A2 (en) 2006-08-17
JP2008529532A (ja) 2008-08-07
EP1851339B1 (en) 2016-05-18
HK1118832A1 (en) 2009-02-20
US20120077201A1 (en) 2012-03-29
ES2586410T3 (es) 2016-10-14
JP2012070746A (ja) 2012-04-12
US8067175B2 (en) 2011-11-29
EP1851339A2 (en) 2007-11-07
US20100173285A1 (en) 2010-07-08
JP4898710B2 (ja) 2012-03-21
EP2505591A1 (en) 2012-10-03

Similar Documents

Publication Publication Date Title
CA2597673C (en) Methods and compositions for detecting a drug resistant egfr mutant
JP6397833B2 (ja) 癌を診断および治療するためのａｌｋの融合に関する方法および組成物
CN107794302B (zh) 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
US20170114417A1 (en) Pkn1 fusions
WO2010123626A1 (en) Cd133 polymorphisms and expression predict clinical outcome in patients with cancer
WO2013172933A1 (en) Ethnic gene profile of genes involved in angiogenesis may predict regional bevacizumab efficacy difference in gastric cancer
WO2011064319A1 (en) Pyrosequencing method for predicting the response of a patient towards anti cancer treatment
CA2617693A1 (en) Composition and method for determination of ck19 expression
US10253370B2 (en) High-sensitivity sequencing to detect BTK inhibitor resistance
HK1118832B (en) Methods and compositions for detecting a drug resistant egfr mutant
Di Trani Role of TP53 mutations and of MRD monitoring by IG/TR rearrangements in refining prognosis of KMT2A-rearranged adult B-lineage Acute Lymphoblastic Leukemia patients
US20110105529A1 (en) ERCC-1 Gene Expression Predicts Chemotherapy Outcome
WO2010124218A2 (en) Genetic variants in il-6, p53, mmp-9 and cxcr predict clinical outcome in patients with cancer
WO2010124215A1 (en) Gene expression levels of egfr, vegfr2, and ercc1 associated with clinical outcomes of chemotherapy
HK1252399B (en) Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
HK1167685B (en) Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
HK1167688B (en) Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
HK1133045A (en) Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250207

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250207